Clinical Trial Update: A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for ASN002 in relapsed/refractory lymphoma and advanced solid tumors; the study status is TERMINATED with results posted in 2023…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• B-cell Leukemia Chronic
• B-lymphocytic Leukemia Chronic
• Cancer
• Chronic Lymphocytic Leukemia
• Idiopathic Myelofibrosis
• Leukemia Lymphocytic Chronic
• Leukemia Lymphocytic Chronic B-cell
• Lymphoma B-cell
• Lymphoma Follicular
• Lymphoma Large B-cell Diffuse
• Lymphoma Malignant
• Lymphoma Mantle-cell
• Lymphoma Non-hodgkin
• Lymphoma T-cell Peripheral
• Myelofibrosis
• Neoplasm
• Peripheral T-cell Lymphoma
• T-cell Lymphoma Peripheral
• Tumor

Drugs mentioned

• ASN002

Snippet

Sponsor: Asana BioSciences | Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-06-07